تقرير
The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
| العنوان: | The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay. |
|---|---|
| المؤلفون: | Malikova I, Husakova M, Bilkova J, Brzezkova R, Hrachovinova I, Kvasnicka T |
| المصدر: | Clinical laboratory [Clin Lab] 2023 Oct 01; Vol. 69 (10). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Clinical Laboratory Publications Country of Publication: Germany NLM ID: 9705611 Publication Model: Print Cited Medium: Internet ISSN: 1433-6510 (Print) Linking ISSN: 14336510 NLM ISO Abbreviation: Clin Lab Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2010- : Mainz : Clinical Laboratory Publications Original Publication: Heidelberg : Verlag Klinisches Labor, [1997- |
| مواضيع طبية MeSH: | Antithrombins*/therapeutic use , Antithrombin III Deficiency*/diagnosis , Antithrombin III Deficiency*/drug therapy, Female ; Humans ; Pregnancy ; Adult ; Antithrombin III/pharmacology ; Thrombin ; Pregnant Women ; Heparin, Low-Molecular-Weight/therapeutic use ; Anticoagulants/pharmacology ; Heparin/pharmacology |
| مستخلص: | Background: We present the case study of a 28-year-old pregnant woman with antithrombin deficiency who was treated with low-molecular-weight heparin (LMWH). Methods: Due to severe homozygous type II antithrombin heparin binding site (HBS) deficiency, the thrombin generation (TG) was monitored in this woman via the Thrombin Generation Assay (TGA). We used Siemens diagnostic kits Berichrom® Antithrombin III (IIa) and INNOVANCE® Antithrombin (Xa) to determine antithrombin activity. We used a chromogenic method for determination of factor Xa (FXa) inhibition. Results: There were no thrombotic complications during the whole pregnancy of the observed woman. Antithrombin was administered before and after delivery, which was significantly reflected in the decrease in thrombin generation. Conclusions: Consistent monitoring of thrombin generation with LMWH anticoagulant therapy administration during pregnancy together with antithrombin administration before and after delivery can improve the overall condition of pregnant women and the quality of their care. |
| المشرفين على المادة: | 0 (Antithrombins) 9000-94-6 (Antithrombin III) EC 3.4.21.5 (Thrombin) 0 (Heparin, Low-Molecular-Weight) 0 (Anticoagulants) 9005-49-6 (Heparin) |
| تواريخ الأحداث: | Date Created: 20231016 Date Completed: 20231101 Latest Revision: 20231101 |
| رمز التحديث: | 20240628 |
| DOI: | 10.7754/Clin.Lab.2023.230435 |
| PMID: | 37844053 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1433-6510 |
|---|---|
| DOI: | 10.7754/Clin.Lab.2023.230435 |